Roche’s cobas EGFR mutation assay, which runs on its cobas 4800 System, is designed to deliver standards in laboratory testing efficiency and medically relevant diagnostic information.

Clovis Oncology’s CO-1686 is currently in pre-clinical development for advanced NSCLC patients.

CO-1686 has been designed to target and covalently bind to the activating and T790M mutant forms of EGFR.

Clovis Oncology president and CEO Patrick Mahaffy said by incorporating a companion diagnostic during clinical development of CO-1686, they reinforce their commitment to focus development programs on specific subsets of cancer populations that are most likely to benefit from their targeted therapies.